The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Poster
Adjusted Ideal Body Weight Dosing Reduces Pharmacokinetics Variability of the PD-L1–Targeted Antibody-Drug Conjugate PDL1V (PF-08046054)
Iboi E, Chia YL, Zhang F, Harrold J, Forero-Torres A, Lamba M, Garg A, Stoelli F
PD-L1-directed Antibody Drug Conjugate | October 21, 2025 | ACoP 2025
C5851001 | NCT05208762
Poster
Encouraging Antitumor Activity of PDL1V (PF-08046054) Monotherapy, an ADC Targeting PD-L1, Correlates with Antigen Expression in Patients with NSCLC
Oliva M, Dowlati A, Desai A, Kotecki N, Saleh R, Sukari A, Burkitt K, Steeghs N, Garralda Cabanas E, Zivi A, Laux D, Gillison M, Patniak A, Minchom A, Ochsenreither S, Ouali K, Le Tourneau C, Gupta S, Zhang R, Fontana E
PD-L1-directed Antibody Drug Conjugate | October 19, 2025 | ESMO 2025
C5851001 | NCT05208762
Presentation
Interim Results of a Phase 1 Study of SGN-PDL1V (PF-08046054) in Patients with PDL1-Expressing Solid Tumors
Oliva M, Ochsenreither S, Le Tourneau C, Champiat S, Saleh R, Burkitt K, Nabell L, Steeghs N, Spreafico A, Minchom A, Patniak A, Call J, Fontana E, Kotecki N, Cabanas G, Zivi A, Riess JW, Gupta S, Zhang R, Gillison M
PD-L1-directed Antibody Drug Conjugate | September 13, 2024 | ESMO 2024
C5851001 | NCT05208762